Literature DB >> 15982723

Clinical implication of laparoscopic pelvic lymphadenectomy in patients with vulvar cancer and positive groin nodes.

Petra Klemm1, Simone Marnitz, Christhardt Köhler, Ute Braig, Achim Schneider.   

Abstract

OBJECTIVE: At present, no clear guidelines for the treatment of patients with vulvar cancer and positive groin nodes exist. In general, the decision for additional pelvic radiation is based on findings by imaging techniques and/or the number of groin nodes involved. The aim of this case series was to demonstrate that histologic result of laparoscopic removed pelvic lymph nodes can be used to select patients who should not undergo pelvic irradiation.
METHODS: From July 1997 to October 2004, 12 consecutive patients with primary or recurrent vulvar cancer underwent laparoscopic pelvic lymphadenectomy following primary or secondary surgical treatment.
RESULTS: There were 8 patients with primary cancer of the vulva and 4 patients with recurrent disease in the inguinal and/or pelvic lymph nodes. The mean age was 61 (26-83) years and the mean body-mass-index was 27.1 (20.8-36.6). Positive groin nodes were found in five patients on the right side and in five patients on the left side; in one patient, positive groin nodes were present in both sides. In another patient with a history of vulvar cancer and positive groin nodes the CT-scan indicated the presence of positive iliac and paraaortic lymph nodes. Only in two patients tumor involved lymph nodes were diagnosed by laparoscopic pelvic lymphadenectomy (one left-sided, one right-sided). The number of harvested pelvic lymph nodes was 13.7 (5-20) in unilateral and 27.8 (16-37) in bilateral lymphadenectomy. The histologic examination of removed pelvic lymph nodes confirmed pelvic radiation in only 2 out of 12 patients, whereas 10 patients were spared from whole pelvis irradiation.
CONCLUSION: With respect to small sample size, laparoscopic lymphadenectomy seems to be a good tool to avoid unnecessary pelvic radiation in patients with vulvar cancer and confirmed positive groin nodes.

Entities:  

Mesh:

Year:  2005        PMID: 15982723     DOI: 10.1016/j.ygyno.2005.05.027

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  7 in total

1.  Diagnosis, Therapy and Follow-up Care of Vulvar Cancer and its Precursors. Guideline of the DGGG and DKG (S2k-Level, AWMF Registry Number 015/059, November 2015.

Authors:  H G Schnürch; S Ackermann; C D Alt; J Barinoff; C Böing; C Dannecker; F Gieseking; A Günthert; P Hantschmann; L C Horn; R Kürzl; P Mallmann; S Marnitz; G Mehlhorn; C C Hack; M C Koch; U Torsten; W Weikel; L Wölber; M Hampl
Journal:  Geburtshilfe Frauenheilkd       Date:  2016-10       Impact factor: 2.915

2.  Therapy for Primary Vulvar Carcinoma.

Authors:  D Herr; I Juhasz-Boess; E F Solomayer
Journal:  Geburtshilfe Frauenheilkd       Date:  2014-03       Impact factor: 2.915

3.  Adjuvant therapy in lymph node-positive vulvar cancer: the AGO-CaRE-1 study.

Authors:  Sven Mahner; Julia Jueckstock; Felix Hilpert; Petra Neuser; Philipp Harter; Nikolaus de Gregorio; Annette Hasenburg; Jalid Sehouli; Annika Habermann; Peter Hillemanns; Sophie Fuerst; Hans-Georg Strauss; Klaus Baumann; Falk Thiel; Alexander Mustea; Werner Meier; Andreas du Bois; Lis-Femke Griebel; Linn Woelber
Journal:  J Natl Cancer Inst       Date:  2015-01-24       Impact factor: 13.506

Review 4.  Vulvar cancer: epidemiology, clinical presentation, and management options.

Authors:  Ibrahim Alkatout; Melanie Schubert; Nele Garbrecht; Marion Tina Weigel; Walter Jonat; Christoph Mundhenke; Veronika Günther
Journal:  Int J Womens Health       Date:  2015-03-20

5.  Invasive Paget's disease of the vulva treated with a combination of surgery and concurrent chemoradiotherapy: A case report.

Authors:  Yoshihide Inayama; Kaoru Abiko; Taito Miyamoto; Akihito Horie; Ken Yamaguchi; Tsukasa Baba; Noriomi Matsumura; Sachiko Minamiguchi; Masaki Mandai
Journal:  Mol Clin Oncol       Date:  2018-09-17

6.  Risk for Pelvic Metastasis and Role of Pelvic Lymphadenectomy in Node-Positive Vulvar Cancer-Results from the AGO-VOP.2 QS Vulva Study.

Authors:  Linn Woelber; Monika Hampl; Christine Zu Eulenburg; Katharina Prieske; Johanna Hambrecht; Sophie Fuerst; Ruediger Klapdor; Sabine Heublein; Paul Gass; Annika Rohner; Ulrich Canzler; Sven Becker; Mareike Bommert; Dirk Bauerschlag; Agnieszka Denecke; Lars Hanker; Ingo Runnebaumn; Dirk M Forner; Fabienne Schochter; Maximilian Klar; Roxana Schwab; Melitta Koepke; Matthias Kalder; Peer Hantschmann; Dominik Ratiu; Dominik Denschlag; Willibald Schroeder; Benjamin Tuschy; Klaus Baumann; Alexander Mustea; Philipp Soergel; Holger Bronger; Gerd Bauerschmitz; Jens Kosse; Martin C Koch; Atanas Ignatov; Jalid Sehouli; Christian Dannecker; Sven Mahner; Anna Jaeger
Journal:  Cancers (Basel)       Date:  2022-01-14       Impact factor: 6.639

7.  Role of Pelvic Lymph Node Resection in Vulvar Squamous Cell Cancer: A Subset Analysis of the AGO-CaRE-1 Study.

Authors:  Linn Woelber; Mareike Bommert; Philipp Harter; Katharina Prieske; Christine Zu Eulenburg; Julia Jueckstock; Felix Hilpert; Nikolaus de Gregorio; Severine Iborra; Jalid Sehouli; Atanas Ignatov; Peter Hillemanns; Sophie Fuerst; Hans-Georg Strauss; Klaus Baumann; Matthias Beckmann; Alexander Mustea; Werner Meier; Sven Mahner; Anna Jaeger
Journal:  Ann Surg Oncol       Date:  2021-03-15       Impact factor: 5.344

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.